Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.70 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.70 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 1/20 | 0.70 |
| ▸ | MMP3 | P08254 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.69 |
| ▸ | USP2 | O75604 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL3155 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL29545414 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41884 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL2221981 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417262 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL3680869 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL28250743 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417256 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL8683380 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL497163 | 0.99 | TDP1 (0.69) | MMP2MMP3MMP7MMP8ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041701-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING ON DEMAND SOLID DOSAGE FORMULATIONS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2026-02-12 | — | — | US | claimed |
| US-12370203-B2 | Pharmaceutical compositions and methods of making on demand solid dosage formulations | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2025-07-29 | — | — | US | claimed |
| US-12285471-B2 | Methods for treating pulmonary disease using inter-alpha inhibitor proteins | PROTHERA BIOLOGICS, INC. (US) | 2025-04-29 | — | — | US | claimed |
| CN-119707728-A | Doxycycline one method for preparing hydrate | 常州齐晖药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-12145951-B2 | Inorganic-organic hybrid compounds including organic platinum-containing anions, for use in medicine | KARLSRUHER INSTITUT FUR TECHNOLOGIE (DE) | 2024-11-19 | — | — | US | claimed |
| CN-118724355-A | Method for treating ammonia nitrogen in doxycycline hydrochloride production wastewater and recycling ammonia nitrogen | 扬州联博药业有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118561712-A | Preparation method of large-particle doxycycline hydrochloride with median particle diameter not less than 40 mu m | 扬州联博药业有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240226000-A9 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240130962-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | claimed |
| US-11839621-B2 | Treatments of prostate cancer | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-12-12 | — | — | US | claimed |
| US-20050019396-A1 | Doxycycline metal complex in a solid dosage form | GALEN (CHEMICALS) LIMITED | 2005-01-27 | — | — | US | claimed |
| EP-1384479-A1 | Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications | G.D. SEARLE & CO. (US) | 2004-01-28 | — | — | EP | claimed |
| US-6550955-B2 | Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface | NORRIS PRIVATE EQUITY, LLC | 2003-04-22 | — | — | US | claimed |
| US-20020044968-A1 | High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion | GENERAL MILLS, INC. | 2002-04-18 | — | — | US | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| US-20010053373-A1 | Process and device for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules | NORRIS PRIVATE EQUITY, LLC | 2001-12-20 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041701-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING ON DEMAND SOLID DOSAGE FORMULATIONS | PGRMC2, RPSA, VMA21 | MMP7 3576/4885MMP8 3819/4885MMP13 1472/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | MMP7 2597/4885MMP8 3576/4885MMP13 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.